Clinical Trial Detail

NCT ID NCT03094611
Title Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

acute lymphocytic leukemia

Therapies

inotuzumab ozogamicin

Age Groups: adult child senior

Additional content available in CKB BOOST